Legend Biotech
Legend Biotech Corporation, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 2014, the company has rapidly established itself as a leader in the development of innovative cell therapies, particularly in the field of oncology.
With a focus on CAR-T cell therapies, Legend Biotech's flagship product, cilta-cel, has garnered significant attention for its unique approach to treating multiple myeloma. The company operates primarily in the US and has expanded its reach into key international markets, enhancing its global footprint.
Recognised for its commitment to advancing healthcare, Legend Biotech has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its position as a trailblazer in the biopharmaceutical landscape.
+19 vs industry average
Legend Biotech’s score of 57 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Legend Biotech?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Legend Biotech's reported carbon emissions
Legend Biotech, headquartered in the US and operating within the Pharmaceutical Preparation Manufacturing industry, reported approximately 12.7 million kg CO2e in Scope 1 and 2 emissions for 2024. For 2023, their Scope 1 and 2 emissions totalled approximately 13.0 million kg CO2e. While specific Scope 3 emissions data for Legend Biotech is not yet available, the company's reporting indicates a focus on Scope 1 and 2 emissions. Their climate commitments and reduction targets are cascaded from Genscript Biotech Corporation. Legend Biotech is a current subsidiary and inherits information regarding SBTi, CDP, and RTZ initiatives from Genscript Biotech Corporation, with Genscript Biotech Corporation being at cascade level 1. The company's emissions data is sourced from Legend Biotech Corporation itself at cascade level 0.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Legend Biotech’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Legend Biotech yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Genscript Biotech Corporation
Carbon Disclosure Project
Inherited from Genscript Biotech CorporationThe Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Genscript Biotech CorporationRE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project